good to hear. As you know I have pointed out that drugs account for a small fraction of health care spending and the constant focus on drug pricing misses the larger picture of run away health care spending in this country (that is not to say there isn't room for some smart drug price reforms)
Echoing what JNJ said last week about Stelara and Xarelto (#msg-174768280), AZN said on today’s 2Q24 CC that the IRA price-setting for Farziga starting in 2026 will have “very limited impact.” Exactly what this phrase means is open to interpretation, but the salient point is that IRA price-setting is apparently not going to be as deleterious to drug/biotech companies as some investors feared.
News 
Market Data 
Discover 
AI
